Taken together with evidence that FGF7 activates FGFR2 in FP‐RMS cells, our data strongly support this ligand‐receptor pairing forming an autocrine loop promoting FP‐RMS cell viability and survival in a similar fashion to that observed in prostate tumors and pre‐adipocytes [56, 57]. Here, FGF7 is linked to prostate neoplasm.